Puma Biotechnology shows a technical breakout and a perfect earnings beat streak, but the stock has already reached its prior price target, faces notable insider selling, and shows heavy bearish options positioning that together argue against adding to the position.
Thesis pillars
- Golden Cross Breakout Setup→Stable
- Perfect Earnings Beat Streak→Stable
- Analyst Target Already Reached→Stable
- +2 more pillars — see the Why tab for full reasoning
Puma Biotechnology Inc (PBYI) Stock Analysis
Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $7.98 — A.R:R is negative (-4.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: NERLYNX.
Puma Biotechnology is a biopharmaceutical company commercializing NERLYNX (neratinib), an oral tyrosine kinase inhibitor approved in the U.S. and more than 40 other countries for extended adjuvant and metastatic HER2-positive breast cancer, marketed domestically through a... Read more
Sell if holding. Analyst target reached at $7.98 — A.R:R is negative (-4.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: NERLYNX. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 5/9 gates (positive momentum, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Puma Biotechnology Inc
About Puma Biotechnology Inc
Puma Biotechnology commercializes NERLYNX (neratinib), its sole revenue-generating product, an oral tyrosine kinase inhibitor approved by the FDA in 2017 for extended adjuvant HER2-positive breast cancer and expanded in February 2020 for metastatic HER2-positive breast cancer in combination with capecitabine. NERLYNX has now received approval in more than 40 countries outside the United States, including the European Union and China, and Puma reported net income in 2025, 2024, and 2023 despite an accumulated deficit of $1,283.8 million as of December 31, 2025.
Puma markets NERLYNX in the United States through a direct specialty sales force of approximately 35 representatives, while pursuing regulatory approval and commercialization outside the U.S. through exclusive sub-license agreements covering Europe, Australia, Canada, China, Southeast Asia, Israel, South Korea, Russia, and parts of Central America, South America, Africa, and the Middle East. In September 2022, Puma in-licensed global development and commercialization rights to alisertib, a selective Aurora Kinase A inhibitor, from a Takeda Pharmaceutical subsidiary, and plans to pursue it in hormone receptor-positive breast cancer and small cell lung cancer using third-party contractors for manufacturing and clinical trial conduct. The company carries $22.5 million outstanding under a Note Purchase Agreement with Athyrium Opportunities IV Co-Invest 1 LP, secured by equity interests in its subsidiaries and substantially all of its property, subject to minimum revenue and cash-balance covenants.
Show full overview
Puma's own risk factors describe the company as a single product company with limited commercial sales experience: NERLYNX is the only product for which Puma currently receives product revenue, and the company expects NERLYNX to constitute the vast majority of its product revenue for the foreseeable future, leaving no ability to spread commercial risk across a broader portfolio. That concentration is compounded by the Athyrium Note Purchase Agreement's minimum product-revenue and cash-balance covenants, which tie Puma's financial flexibility directly to NERLYNX's continued commercial performance while the company's second asset, alisertib, remains in early-stage development with no near-term revenue contribution.
See also: Healthcare · Biotechnology
From Puma Biotechnology Inc's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-26Recent Developments — Puma Biotechnology Inc
Latest news
- NEWS 12 Health Care Stocks Moving In Tuesday's After-Market Session — benzinga Jul 7, 2026 neutral
Generated 2026-07-26T14:07:16Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductNERLYNX10-K Item 1A: 'NERLYNX is the only product for which we currently receive product revenue, and we expect NERLYNX to constitute the vast majority of our product revenue for the foreseeable future.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Revenue shrinking — -2.6% YoY. Growth thesis broken unless recovery story develops.static
Negative sentiment — recent news tone and/or analyst downgrades drag the composite below neutral.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $7.98 — A.R:R is negative (-4.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: NERLYNX. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $7.42. Score 5.1/10, moderate confidence.
Take-profit target: $8.57 (-46.7% upside). Prior stop was $7.42. Stop-loss: $7.42.
Concentration risk — Product: NERLYNX; Analyst target reached - limited upside remaining; Weak growth.
Puma Biotechnology Inc trades at a P/E of 16.6 (forward 22.8). TrendMatrix value score: 6.5/10. Verdict: Sell.
6 analysts cover PBYI with a consensus score of 2.2/5. Average price target: $5.
What does Puma Biotechnology Inc do?Puma Biotechnology is a biopharmaceutical company commercializing NERLYNX (neratinib), an oral tyrosine kinase...
Puma Biotechnology is a biopharmaceutical company commercializing NERLYNX (neratinib), an oral tyrosine kinase inhibitor approved in the U.S. and more than 40 other countries for extended adjuvant and metastatic HER2-positive breast cancer, marketed domestically through a roughly 35-person specialty sales force and internationally through exclusive sub-licensees. The company is also developing alisertib, an Aurora Kinase A inhibitor in-licensed from Takeda in September 2022 for hormone receptor-positive breast cancer and small cell lung cancer. Puma is a single-product company: NERLYNX is its